Table 2.
Effectiveness in individuals aged 18–64 years in the B.1.617.2-dominant period
| VE (95% CI) | BNT162b2: one dose ≥21 d | ChAdOx1: one dose ≥21 d | BNT162b2: second dose 0–13 d ago | ChAdOx1: second dose 0–13 d ago | BNT162b2: second dose ≥14 d | ChAdOx1: second dose ≥14 d | Not vaccinated, previously positivea |
|---|---|---|---|---|---|---|---|
| All infections (Fig. 1a) | 58% (51–63%) | 43% (31–52%) | 83% (76–88%) | 71% (63–77%) | 82% (79–85%) | 67% (62–71%) | 73% (59–82%) |
| Ct <30 (Fig. 1b) | 63% (57–68%) | 48% (38–57%) | 81% (73–86%) | 69% (61–76%) | 86% (84–88%) | 69% (65–73%) | 78% (66–85%) |
| Self-reported symptoms (Fig. 1c) | 59% (52–64%) | 36% (23–47%) | 93% (90–95%) | 72% (65–78%) | 86% (83–88%) | 70% (66–74%) | 83% (74–88%) |
| Ct ≥30 | 40% (31–48%) | 27% (12–39%) | 87% (82–91%) | 74% (66–79%) | 71% (65–75%) | 59% (53–64%) | 57% (35–72%) |
| No self-reported symptoms | 55% (48–61%) | 50% (40–58%) | 58% (41–70%) | 66% (57–73%) | 74% (69–78%) | 57% (51–63%) | 51% (26–67%) |
aRe-infection will be a variable amount of time previously, but it was not possible to split this owing to low numbers.
Note: All estimates (VE = 100% × (1 odds ratio)) as shown in Fig. 1 were obtained from a generalized linear model with a logit link comparing to the reference category of ‘Not vaccinated, not previously positive and ≥21 d before vaccination’ and using clustered robust standard errors. Heterogeneity P values were obtained using the two-sided Wald test without adjustment for multiple comparisons. See Supplementary Table 5 for unadjusted heterogeneity P values. See Table 1 for estimates in individuals ≥18 years of age in both B.1.1.7-dominant and B.1.617.2-dominant periods. VE post-second doses changes over time from vaccination (Fig. 2 and Extended Data Figs. 4 and 5), so estimates in this table are an average over follow-up included in this analysis.